New drug products developed by domestic pharmaceutical companies with their own technologies are accelerating their targeting in the global market. However, some point out that it is difficult to predict commercial success because there are many variables such as the situation of the local market even if they have reserved to enter the overseas market.

◆K-Cab Expands to 34 Export Contracting Countries...Maximum contract size of ↑1 trillion won

According to the industry on the 11th, HK inno.N signed a contract with Indian pharmaceutical company Dr. Reddy's Laboratories to export new K-Cab for gastroesophageal reflux disease. Seven countries have signed export contracts, including